Abstract
Contrast-induced nephropathy (CIN) is a type of acute kidney injury associated with intravascular administration of iodinated contrast, usually reversible. Contrast agents are an essential component of invasive and noninvasive coronary angiography. These agents have been modified over time to enhance patient safety and tolerability, but adverse reactions still occur. CIN has been variably defined, as a rise in serum creatinine of 0.5 mg/dl, or a 25% increase in serum creatinine above baseline within 24-72 hours after the procedure. The incidence of CIN varies based on the definition used and risk profile of the patients. CIN is rare among patients with normal renal function at baseline. In low-risk patients, CIN occurs in 1-5%, whereas in higher-risk populations, the incidence can be as high as 30%. CIN is also associated with a 5- to 20-fold increased risk of other early adverse events including in-hospital myocardial infarction, target vessel occlusion, and early mortality. The main prevention strategies are adequate intravenous hydration before, during and after the procedure as well as restriction of contrast load with maximum volume approximately no more than three times the serum creatinine clearance. Recent observational and small prospective randomized trials demonstrate the reduction of CIN incidence with HMG-CoA enzyme inhibitors. In this systematic review and meta-analysis we explore the effects of statin administration in prevention of CIN.
Keywords: Statins, contrast induced nephropathy, meta-analysis, kidney, coronary angiography, intravenous hydration.
Current Pharmaceutical Design
Title:Statins and Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis
Volume: 23 Issue: 46
Author(s): Alexandros Briasoulis*, Mohan Pala, Tesfaye Telila, Obsinet Merid, Emmanuel Akintoye, Georgia Vogiatzi, Evangelos Oikonomou and Dimitris Tousoulis
Affiliation:
- Division of Cardiovascular Diseases, Mayo Clinic, Rochester MN,United States
Keywords: Statins, contrast induced nephropathy, meta-analysis, kidney, coronary angiography, intravenous hydration.
Abstract: Contrast-induced nephropathy (CIN) is a type of acute kidney injury associated with intravascular administration of iodinated contrast, usually reversible. Contrast agents are an essential component of invasive and noninvasive coronary angiography. These agents have been modified over time to enhance patient safety and tolerability, but adverse reactions still occur. CIN has been variably defined, as a rise in serum creatinine of 0.5 mg/dl, or a 25% increase in serum creatinine above baseline within 24-72 hours after the procedure. The incidence of CIN varies based on the definition used and risk profile of the patients. CIN is rare among patients with normal renal function at baseline. In low-risk patients, CIN occurs in 1-5%, whereas in higher-risk populations, the incidence can be as high as 30%. CIN is also associated with a 5- to 20-fold increased risk of other early adverse events including in-hospital myocardial infarction, target vessel occlusion, and early mortality. The main prevention strategies are adequate intravenous hydration before, during and after the procedure as well as restriction of contrast load with maximum volume approximately no more than three times the serum creatinine clearance. Recent observational and small prospective randomized trials demonstrate the reduction of CIN incidence with HMG-CoA enzyme inhibitors. In this systematic review and meta-analysis we explore the effects of statin administration in prevention of CIN.
Export Options
About this article
Cite this article as:
Briasoulis Alexandros*, Pala Mohan, Telila Tesfaye , Merid Obsinet, Akintoye Emmanuel , Vogiatzi Georgia, Oikonomou Evangelos and Tousoulis Dimitris , Statins and Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis, Current Pharmaceutical Design 2017; 23 (46) . https://dx.doi.org/10.2174/1381612823666170913170527
DOI https://dx.doi.org/10.2174/1381612823666170913170527 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Enhancement of IL-2 Through Molecular Design
Current Pharmaceutical Design Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
Current Hypertension Reviews Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Agonistic and Antagonistic Bivalent Ligands for Serotonin and Dopamine Receptors Including their Transporters
Current Topics in Medicinal Chemistry Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension
Current Protein & Peptide Science Malaria Stage-Specific Vaccine Candidates
Current Pharmaceutical Design A Paradigm Shift in the Development of Anti-Candida Drugs
Current Topics in Medicinal Chemistry Renal Complications of Fabry Disease
Current Pharmaceutical Design Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Adverse HBOC-Endothelial Dysfunction Synergism: A Possible Contributor to Adverse Clinical Outcomes?
Current Drug Discovery Technologies Antipsychotic Drugs and Cerebrovascular Events in Elderly Patients with Dementia: A Systematic Review
Mini-Reviews in Medicinal Chemistry Antimicrobial Stewardship in the Neonatal Intensive Care Unit: An Update
Current Pediatric Reviews Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology The Future of Interventional Management of Hypertension: Threats and Opportunities
Current Vascular Pharmacology Pulmonary Embolism Response Team (PERT) - A New Paradigm for the Treatment of Pulmonary Embolism
Current Pharmaceutical Design Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Integrating Pharmacogenetics for Assessment of Herb-Drug Interactions: Has the Time Come?
Current Pharmacogenomics and Personalized Medicine Contractile Mechanisms in Diabetes-Related Erectile Dysfunction
Current Pharmaceutical Design Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews Review of Vital Signs Monitoring Systems – Patient’s Acceptability, Issues and Challenges
Neuroscience and Biomedical Engineering (Discontinued)